Traditional hybridoma and phage display methods have failed to yield therapeutic antibodies against difficult targets like most GPCRs and ion channels. This presentation will introduce Berkeley Lights’ new Opto™ Plasma B Discovery 4.0 workflow that enables recovery of 1000s of hits by screening up to 100,000 plasma B cells, down-selection of lead candidates by functional screening, and sequencing and re-expression of >1000 functionally-characterized antibodies … all in just 1 week. By maximizing the diversity of antibodies through direct functional profiling of plasma B cells, the Opto Plasma B Discovery 4.0 workflow will allow users to tackle even the most challenging targets.
1. Identify the limitations on hybridoma approaches
2. Understand the unique advantages of the Berkeley Lights Platform
3. Explore current data and case studies behind accelerated discovery against difficult targets